ImmunityBio, Inc. Common Stock
Here’s whether ImmunityBio, Inc. Common Stock (IBRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+2.76% over 10 days); RSI 53 — healthy momentum range; strong 1-year return of +210.5%; 3-month momentum positive (+39.5%). Concerns: below the 50-day MA (medium-term momentum negative); declining volume on rally — weak conviction (0.68x 30d avg). Currently 38.0% off its 52-week high. Score: +4/7.
IBRX is holding above its long-term 200-day MA ($4.06) but has slipped below the 50-day MA ($7.97), pointing to short-term weakness in an otherwise intact trend. An RSI of 53.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +210.5% compares to +35.1% for SPY (beat the market by 175.4%). The current 38.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.